|Articles|June 11, 2020
Episode 58: Understanding FDA’s Gene Therapy Guidelines
Author(s)Elaine Quilici
Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Senior Vice President of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.
Advertisement
Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Managing Director of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement
2
FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia
3
From Dr. Google to Dr. Claude: Why the Most Important Patient Support Innovation Is Still Human Connection
4
Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta
5